RxDoctor Payments Data

Ashlee Costa

Psychiatric/Mental Health · Greenfield, MANPI 1881338648

Payments from drug & device makers

$1,651in general payments, 2019–2025

Across 75 payments — averaging $22.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$408
  • Otsuka America Pharmaceutical, Inc.$226
  • Vanda Pharmaceuticals Inc.$137
  • Indivior Inc.$137
  • AbbVie$134
  • Alkermes, Inc.$118
  • plus $490 from 11 others

What the payments were for

  • Food & beverage$1,51492%
  • Education$1378%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,651 in reported general payments places this provider in the 85th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

See all psychiatric/mental health providers in Massachusetts

Medicare billing

Part B allowed, 2024
$30,491
Medicare patients
53
Services billed
259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl143$170,670
VraylarCariprazine Hcl59$87,977
SublocadeBuprenorphine25$51,647
RexultiBrexpiprazole29$46,058
Invega SustennaPaliperidone Palmitate11$34,714
VivitrolNaltrexone Microspheres21$33,782
AustedoDeutetrabenazine12$33,391
LybalviOlanzapine/Samidorphan Malate16$28,465
CaplytaLumateperone Tosylate15$26,473
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl90$14,093
Aripiprazole83$11,661
Lisdexamfetamine Dimesylate38$7,630
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine130$3,736
Gabapentin131$2,886
Topiramate83$2,422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato, Invega Sustenna$408$205,384154 claims
AbbVieVraylar$134$87,97759 claims
Alkermes, Inc.Vivitrol, Lybalvi$118$62,24737 claims
Indivior Inc.Sublocade$137$51,64725 claims
Otsuka America Pharmaceutical, Inc.Rexulti$226$46,05829 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$99$26,47315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,284 psychiatric/mental health providers in Massachusetts.

Other psychiatric/mental health in Greenfield

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →